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Abstract
Introduction
Wheezing is common in young children. By the age of six, approximately 50% of children
in high-income countries will have experienced at least one episode of wheezing in their life.
Furthermore, childhood wheezing may be associated with reduced lung function and increased
risk of asthma in later life. Determining the epidemiology of wheeze is complex given that the
risk factors vary based on the age of the child and the phenotype of wheeze. Little is known
regarding the recurrent nature of childhood wheezing in low- and middle-income contexts. This
study aimed to use multi-state models to estimate the rate of transition among various states of
wheeze in children from birth to the age of three years. This study also aimed to investigate the
association between possible risk factors for childhood wheezing and the estimated transition
intensities.
Methods
The rationale for conducting the study, as well as the objectives of the study, methods and data
analysis plan are outlined in the study protocol (Part A). A summary of what is currently known
about childhood wheezing is presented as part of the literature review (Part B). The aim of
the literature review was to identify known risk factors for childhood wheeze and the methods
used to analyse recurrent childhood wheezing, as well as identify the limitations of the current
methods used to analyse recurrent childhood wheezing. A manuscript presenting the results of
the study is included as Part C.
This study was a secondary analysis of data from 1086 children from birth to three years, born
to mothers in the Drakenstein area of theWestern Cape, South Africa, enrolled at one of two pri-
mary care clinics. The data were collected as part of a prospective birth cohort, the Drakenstein
Child Health Study. Cox proportional hazards models were used to investigate the association
of risk factors with time to first wheezing event and time to recurrent wheezing. Two multi-
state models investigating the progression of childhood wheezing were constructed. Multiple
definitions of childhood wheeze as an outcome were investigated for all constructed models.
A simple unidirectional multi-state model and a complex multi-state model with three states
(never wheeze, wheeze not associated with lower respiratory tract infection (LRTI), and, lower
respiratory tract infection associated wheeze) were constructed. The multi-state model allowed
four possible transitions: 1) from “never wheeze” to “wheeze not associated with LRTI” or from
2) “never wheeze” to “LRTI-associated wheeze” or from 3) “wheeze not associated with LRTI”
to “LRTI-associated wheeze” and from 4) “LRTI-associated wheeze” to “wheeze not associated
with LRTI”. Transition intensities between wheeze states were estimated using discrete time
multi-state models. The association of risk factors with transition intensities were estimated
using multivariable proportional hazards models.
Results
Of the 1086 children included in the study, 476 (44%) experienced at least one episode of wheez-
ing, and 227 (21%) experienced more than one episode of wheezing in the first three years of
life. A total of 951 episodes of wheezing were recorded in the 36 months of follow-up time.
In the multi-state analysis, LRTI-associated wheeze and wheeze not associated with LRTI were
equally likely to be the first wheeze event. However, recurrent wheezing events were more
likely to follow LRTI-associated wheeze as the first event (0.0020033 vs 8.6683754 × 10−4).
Male children were at significantly higher risk of experiencing wheeze associated with an LRTI
as the first wheezing event and at significantly higher risk of subsequent recurrent wheezing.
Children exposed to maternal smoking prenatally had a significantly higher risk of transition to
the wheeze state compared to unexposed children.
Conclusion
Multi-state models provide a novel method for the analysis of wheezing and recurrent wheezing
in a cohort of children in South Africa. Multi-state models successfully predicted the progres-
sion of children through discrete states of wheeze and produced results consistent with existing
literature on childhood wheeze, while accounting for recurrent events and interval-censored
data.
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Introduction
Wheeze is associated with much of the non-communicable childhood morbidity and mortality
in many low- and middle-income countries (LMICs), as well as pneumonia. The primary aim
of the study is to make use of multi-state models to estimate the transition probabilities and risk
factors associated with the development of wheeze and recurrent wheeze in a cohort of Western
Cape children followed for at least five years following birth. Secondary aims of the study are
to compare results from traditional survival analysis of wheeze to the results of analysis done
using multi-state models.
Background
Globally, respiratory diseases are a major cause of morbidity and mortality, particularly in child-
hood1. It is estimated that respiratory diseases affect more than 400 million people annually
around the world2. However, although respiratory infections are common globally, severe mor-
bidity and mortality are associated largely with LMICs. Lower respiratory tract infections are
responsible for roughly 652 572 (586 475 – 720 612) deaths annually in children under the age
of five around the globe2–4. It is estimated that 90% of the childhood deaths associated with
lower respiratory tract infections occur in LMICs4,5.
Of particular concern in children in LMICs are wheeze and asthma, given that treatment and
care of asthma place a considerable drain on the resources of already strained or resource-poor
healthcare systems. Wheeze is defined as a continuous, coarse, whistling sound produced during
breathing6. Wheezing is caused by restricted respiratory passages, however, diagnosis is chal-
lenging given wheezing is a symptom of many related respiratory diseases, such as pneumonia.
According to Pearce et al. [7] asthma symptoms, defined as wheezing in the last 12 months,
2 of 73
are prevalent in roughly 11.5% of children aged six to seven around the globe. However, in
Africa, the overall prevalence of asthma symptoms in children aged six to seven is estimated
to be 5.6%, and the prevalence of asthma symptoms in children aged thirteen to fourteen is es-
timated to be 13.4%. The estimated prevalence of asthma symptoms in children aged thirteen
to fourteen in Cape Town is higher than both the global and African estimates, with 20.3% of
children experiencing wheeze8.
The high burden of wheeze has generated interest in the risk factors associated with wheeze.
There is evidence that wheezing is associated with respiratory syncytial virus (RSV) and asthma
in children9,10. Furthermore, wheezing has been shown to be associated with gender and race in
children in the United States, with black male children being at the highest risk of wheezing11.
However, much of the work on wheeze and its associations has been conducted in high-income
countries, it is not known if these risk factors are the same in LMICs. Furthermore, much of the
existing work on wheeze has focused on wheeze, or recurrent wheeze as a single outcome, and
has not made use of methods of analysis that allow for the incorporation of repeated outcome
measures or recurrent events within an individual.
One method of accounting for recurring events in the analysis of longitudinal data is the use
of multi-state models. Multi-state models create defined states, such as ”healthy”, ”sick”, and
”recovered/dead” and allow for participants in the study to occupy a given state and the transition
to a different state in discrete time intervals. By creating defined states for participants to enter,
multi-state models allow for analysis of recurrent events and the risk factors associated with
them. Multi-state models have been used successfully in the analysis of HIV in a cohort in
which there was incomplete disease history as well as incomplete information with regards to
transition times between states12. Similarly, multi-state models have been used in the analysis
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of asthma control, in order to determine the risk factors associated with optimal asthma control
and sub-optimal asthma control13. Furthermore, multi-state models are useful in the analysis of
datasets containing repeated measures. Multi-state models have been used to deal with repeated
measures in the analysis of risk factors associated with survival in cancer patients14, as well as
determining risk factors associated with possible recurrent episodes of colon cancer15.
Given that wheeze can recur multiple times throughout childhood, as well as the age-related
change in risk factors for wheeze, multi-state models are ideal for determining the factors as-
sociated with wheeze in a resource-poor health care context. Therefore, this cohort study seeks
to estimate the transition probabilities and risk factors associated with the first wheeze event as
well as recurrent wheezing events by making use of multi-state models in a resource-poor health
care setting in the Western Cape, South Africa.
Methods
Study Design
The study will be a secondary data analysis of data generated by the Drakenstein Child Health
Study (DCHS), a population based-birth cohort study investigating the epidemiology and aeti-
ology of childhood respiratory illness and the determinants of child health in a peri-urban area
in South Africa16.
The study will include 1086 mother-child pairs enrolled in the Drakenstein Child Health Study.
Wheezing symptoms are expected to occur in roughly 30% of the children participating in the
study. The primary outcome of interest will be wheezing symptoms as indicated by case-report
forms. Firstly, wheezing was identified by parental report as a positive answer to the ques-
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tion “Has your child had a wheezing or whistling noise coming from his/her chest in the past 6
months?”. Secondly, trained healthcare workers recorded if a child had wheezing evident while
present at a study or sick visit. Identification of wheezing could occur at planned study visits
or at unscheduled visits for LRTI. Recurrent wheezing was defined as two or more episodes
of wheezing, either parental report or healthcare worker observed, within a twelve month pe-
riod.
Characteristics of the Study Population
The data for this study is provided by the parent study, as such data collection for this study has
already been completed. The study population consisted of participants enrolled in the parent
study (DCHS). The study participants were located in the Drakenstein area in Paarl, an area with
a population of roughly 200,000. Members of the Drakenstein community are of low socio-
economic status and live in informal housing or crowded conditions. There is a high prevalence
of various poverty-related exposures, such as tobacco smoke exposure, alcohol misuse, and
malnutrition. More than 90% of the populationmake use of the freely available public healthcare
system. The public health system in the Drakenstein area is comprised of 23 primary care clinics
and one hospital, Paarl Hospital, where all births and hospital care occur16.
Participants in the parent study are children born to mothers in the Drakenstein area that made
use of one of the two primary care clinics that serve as enrolment sites and who intended to
remain in the area for at least a full year following enrolment. The two primary care clinics serve
two different populations, TC Newman (serving a mixed-ancestry population) and Mbekweni
(serving a black African population).
The inclusion of pregnant women and mother-child pairs constitutes the inclusion of vulnerable
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groups. However, the inclusion of these vulnerable groups is strictly necessary given the high
morbidity and mortality caused by respiratory diseases in children. Furthermore, wheezing is
primarily diagnosed in young children, and thus can best be studied in young children. It is
important to note that the Drakenstein community has both high-levels of poverty related ex-
posures as well as high-levels of access to primary healthcare and might not be generalizable
to low-income and middle-income countries with lower levels of access to primary healthcare.
However, as countries improve access to health services these results are likely to becomewidely
applicable in low-income and middle-income countries.
Recruitment and Enrolment
The data for this study will be provided by the parent study (DCHS). In the DCHS, pregnant
women who had attended either the TC Newman or Mbekweni primary care clinics and who
were 20 - 28 weeks gestation age were recruited for the study. Pregnant women who consented
to participate in the study completed study questionnaires at scheduled study follow-up visits.
Child clinical and respiratory symptoms were completed at each of the study visits, which oc-
curred at birth, 6, 10, and 14 weeks as well as at 6, 12, 18, and 24 months post-delivery at the
primary care clinics. All data collected in the DCHS were collected by trained study staff. Staff
included research nurses and clinicians at the two primary care clinics. No new individuals will
be recruited or enrolled for the current study.
Research Procedures and Data Collection Methods
Given that this study is an analysis of secondary data provided by the DCHS, no participants
will be subject to any medical, behavioural or observational interventions. The DCHS staff
measured childhood wheezing by parental report as well as active surveillance during lower
6 of 73
respiratory tract infections that required clinic or hospital care. Maternal health and associated
risk factors were assessed by means of a standardized questionnaire of relevant demographic
and clinical information administered by trained study staff. Lung function in the children was
tested at six weeks of age and annually thereafter at Paarl Hospital. All data collection proce-
dures in the parent study have been approved by the UCT Human Research Ethics Committee
(HREC), University of Cape Town (401/2009) and theWestern Cape Provincial Health Research
committee.
Data Safety and Monitoring
Data collected for use in this study, by the parent study (DCHS), does not consist of any iden-
tifying information about the participants in the study. However, in order to further protect the
information of the participants in the study, all study data will be password-protected.
Data Analysis
Data collected for use in this study, by the parent study (DCHS), consists of standardized ques-
tionnaires of demographic and clinical information as well as case-report forms completed by
study personnel during planned routine study visits and after discharge from hospital in children
admitted for pneumonia and four weeks after an inpatient or ambulatory pneumonia. The data
provided for this study will contain no identifying information, all participants are provided with
a unique participant-ID that will be used for the purposes of the study.
Initial descriptive analysis of the data will include estimation of medians and proportions as
necessary. Cox proportional hazards models will be used to estimate the time to first wheezing
event, as well as time to recurrent wheezing17. Multi-state Markov models will be used to es-
timate transition probabilities as well as factors associated with the transition between defined
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states. The multi-state models will be created and transition probabilities, as well as risk factors
associated with transition, will be determined using the msm package18 in R. All analysis will
be done using the open-source statistical programming language R19.
Description of Risks and Benefits
There are no direct risks to the study participants as this study is an analysis of secondary data
generated by the parent study (DCHS). Given the nature of the study, the potential risks for
participants involve loss of confidentiality or stigmatization if sensitive information about the
participants, provided for use in the study, is made public. Therefore, in order to minimise
the potential risks to study participants, the data requested from the parent study will contain
no identifying information. Participants will be identified only by the unique participant-ID
assigned to them at enrolment into the study.
While this research is not expected to directly benefit the participants of this study, the study
is expected to generate information that may contribute to the knowledge about the risk factors
associated with wheezing episodes in young children, and may, therefore, allow study partici-
pants and the population, in general, to be more informed about possible risk factors that may
lead to the development of wheeze in children. Given the minimal risks to the participants and
the potential long-term benefits the results of the study may provide to participants, we believe
that the study is justified.
Informed Consent Process
Informed consent was obtained in writing at the primary care clinic at the time of enrolment.
Mothers were not coerced or influenced in any other way to participate in the study. Informed
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consent forms were provided to the mothers in one of three languages of their choosing, either
English, Afrikaans or isiXhosa. Informed consent was obtained by study personnel trained to
assist the mothers in completing the informed consent forms in the chosen language, and is
renewed annually. Consent from each mother in the study was renewed annually.
All the adult participants in the DCHS have the capacity to consent. Given that the infants
participating in the study are aged 0 - 24 months, consent for infant participation was sought
from the mother of the infant as well as the father if possible. The participants can remove
themselves from the study at any time should they feel the need to. Furthermore, participants
are informed that they may refuse to participate in any aspect of the study and sub-studies but
remain in the study. It is also made clear that should participants refuse to participate in any part
of the study it will in no way affect the treatment and care they receive at the primary care clinic
that they visit.
Privacy and Confidentiality
The data obtained for this study from the DCHS parent study contains no identifying informa-
tion, all participants are listed by their unique participant-ID only. Only the study coordinators
of the DCHS have access to the full linked study data. In order to maintain privacy in the parent
study, all interviews with participants were conducted in private, with only the study participant
and the researcher present. All information gathered in the study is stored in a locked filing
system at the two primary care clinics serving as study sites. Data is abstracted and stored in a
password protected REDCap database, with access restricted to the primary study investigator
and study personnel tasked with monitoring the data in the database.
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Reimbursement for Participation
Not applicable as the study is an analysis of secondary data.
Emergency care and insurance for research-related injuries
Not applicable as the study is an analysis of secondary data.
Dissemination of Research Findings
The proposed study will be submitted as a mini-dissertation in partial fulfilment of the require-
ments for a Master of Public Health degree at the University of Cape Town. A manuscript
describing the findings of this study will be prepared for submission to a relevant peer-reviewed
journal.
10 of 73
References
1. Zar, H. J. and Ferkol, T. W. “The Global Burden of Respiratory Disease-Impact on
Child Health”. In: Pediatric Pulmonology 49.5 (Mar. 2014), pp. 430–434. ංඌඌඇ:
87556863. ൽඈං: 10.1002/ppul.23030.
2. Mathers, C., Fat, D. M., Boerma, J. T., and World Health Organization, eds. The Global
Burden of Disease: 2004 Update. OCLC: ocn264018380. Geneva, Switzerland: World
Health Organization, 2008. 146 pp. ංඌൻඇ: 978-92-4-156371-0.
3. Leowski, J. “Mortality from acute respiratory infections in children under 5 years of
age: global estimates”. In:World Health Statistics Quarterly 39.2 (Apr. 1986),
pp. 138–144. ංඌඌඇ: 0379-8070.
4. Troeger, C. et al. “Estimates of the Global, Regional, and National Morbidity, Mortality,
and Aetiologies of Lower Respiratory Infections in 195 Countries, 1990–2016: A
Systematic Analysis for the Global Burden of Disease Study 2016”. In: The Lancet
Infectious Diseases 18.11 (Nov. 2018), pp. 1191–1210. ංඌඌඇ: 1473-3099. ൽඈං:
10.1016/S1473-3099(18)30310-4.
5. Nair, H. et al. “Global and Regional Burden of Hospital Admissions for Severe Acute
Lower Respiratory Infections in Young Children in 2010: A Systematic Analysis”. In:
The Lancet 381.9875 (Apr. 2013), pp. 1380–1390. ංඌඌඇ: 1474-547X
(Electronic)\r0140-6736 (Linking). ൽඈං: 10.1016/S0140-6736(12)61901-1.
6. Kliegman, R. M., Behrman, R. E., Jenson, H. B., and Stanton, B. M. D. Nelson Textbook
of Pediatrics. Elsevier Health Sciences, Aug. 15, 2007. 3200 pp. ංඌൻඇ:
978-1-4377-2180-5.
7. Pearce, N. et al. “Worldwide Trends in the Prevalence of Asthma Symptoms: Phase III
of the International Study of Asthma and Allergies in Childhood (ISAAC)”. In: Thorax
62.9 (May 2007), pp. 757–765. ංඌඌඇ: 0040-6376. ൽඈං: 10.1136/thx.2006.070169.
8. Zar, H. J., Ehrlich, R. I., Workman, L., and Weinberg, E. G. “The Changing Prevalence
of Asthma, Allergic Rhinitis and Atopic Eczema in African Adolescents from 1995 to
2002”. In: Pediatric Allergy and Immunology 18.7 (Nov. 2007), pp. 560–565. ංඌඌඇ:
0905-6157, 1399-3038. ൽඈං: 10.1111/j.1399-3038.2007.00554.x.
9. Stein, R. T. et al. “Respiratory Syncytial Virus in Early Life and Risk of Wheeze and
Allergy by Age 13 Years”. In: The Lancet 354.9178 (Aug. 1999), pp. 541–545. ൽඈං:
10.1016/S0140-6736(98)10321-5.
10. Lee, D. A., Winslow, N. R., Speight, A. N., and Hey, E. N. “Prevalence and Spectrum of
Asthma in Childhood.” In: British Medical Journal 286.6373 (Apr. 1983), pp. 1256–8.
ංඌඌඇ: 0267-0623 (Print)\r0267-0623 (Linking).
11 of 73
11. Gergen, P. J., Mullally, D. I., Evans, R., and Gergen, J. “National Survey of Prevalence
of Asthma among Children in the United States, 1976 to 1980”. In: Pediatrics 81.1 (Jan.
1988), pp. 1–7.
12. Gentleman, R. C., Lawless, J. F., Lindsey, J. C., and Yan, P. “Multi‐state Markov
Models for Analysing Incomplete Disease History Data with Illustrations for Hiv
Disease”. In: Statistics in Medicine 13.8 (Apr. 1994), pp. 805–821. ංඌඌඇ: 0277-6715
(Print)\r0277-6715 (Linking). ൽඈං: 10.1002/sim.4780130803.
13. Saint-Pierre, P., Combescure, C., Daurès, J., and Godard, P. “The Analysis of Asthma
Control under a Markov Assumption with Use of Covariates”. In: Statistics in Medicine
22.24 (Dec. 2003), pp. 3755–3770. ංඌඌඇ: 0277-6715\r1097-0258. ൽඈං:
10.1002/sim.1680.
14. Kay, R. “A Markov Model for Analysing Cancer Markers and Disease States in
Survival Studies”. In: Biometrics 42.4 (Dec. 1986), pp. 855–855. ංඌඌඇ: 0006-341X
(Print). ൽඈං: 10.2307/2530699.
15. Conlon, A. S., Taylor, J. M., and Sargent, D. J. “Multi-State Models for Colon Cancer
Recurrence and Death with a Cured Fraction”. In: Statistics in Medicine 33.10 (Dec.
2013), pp. 1750–1766. ංඌඌඇ: 0277-6715. ൽඈං: 10.1002/sim.6056.
16. Zar, H. J., Barnett, W., Myer, L., Stein, D. J., and Nicol, M. P. “Investigating the
Early-Life Determinants of Illness in Africa: The Drakenstein Child Health Study”. In:
Thorax 70.6 (June 2015), pp. 592–594. ංඌඌඇ: 0040-6376, 1468-3296. ൽඈං:
10.1136/thoraxjnl-2014-206242.
17. Cox, D. R. “Regression Models and Life-Tables”. In: Journal of the Royal Statistical
Society: Series B (Methodological) 34.2 (Mar. 1972), pp. 187–202. ංඌඌඇ: 2517-6161.
ൽඈං: 10.1111/j.2517-6161.1972.tb00899.x.
18. Jackson, C. H. “Multi-State Models for Panel Data: The Msm Package for R”. In:
Journal of Statistical Software 38.8 (Apr. 2011). ංඌඌඇ: 1548-7660. ൽඈං:
10.18637/jss.v038.i08.
19. R Core Team. R: A Language and Environment for Statistical Computing. Vienna,
Austria: R Foundation for Statistical Computing, July 2018.
12 of 73
Part B: Literature Review
13 of 73
Literature Review Objectives
The objectives of this structured literature review are as follows: to present literature on the
known risk factors for childhoodwheezing, recurrent childhoodwheezing, and childhoodwheez-
ing associated with respiratory tract infections. Furthermore, the review aims to examine the
statistical methods used for the analysis of longitudinal data and repeated measures with regards
to childhood wheezing. Finally, this review will discuss the limitations of the current literature
with respect to childhood wheezing and the need for further research.
Search Strategy
Initial searches were conducted using PubMed, Google Scholar and Scopus. Search terms used
were: “(child OR childhood) AND (wheeze OR wheezing OR wheezing symptoms OR wheez-
ing illness) AND (risk factor)”. Further information on recurrent and severe childhoodwheezing
was searched for in the same databases using the following search terms: “(child OR childhood)
AND (wheeze OR wheezing OR wheezing symptoms OR wheezing illness) AND (severe OR
recurrent OR persistent)”. Additional articles were identified from reference lists and bibliogra-
phies of articles extracted by the initial search.
Only studies conducted in English were considered for the structured literature review. The
articles included in the review were not limited to a particular timeframe, although any articles
that did not include childhood wheezing as an outcome were excluded. Furthermore, all study
designs were considered, however, prospective longitudinal study designs were of particular
importance. One study could not be obtained from the databases or contact with the authors
and was therefore excluded, all other studies found were considered for the summary of the
literature.
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Summary of the Literature
The Epidemiology of Wheeze
Determining the epidemiology and risk factors for childhood wheezing is complex, given that
wheezing is a symptom of many related respiratory diseases such as asthma, pneumonia and
other respiratory infections1. Another challenge in determining the risk factors associated with
wheezing is the lack of standardisation in the definition of wheezing as an outcome. There is
currently no agreed upon definition of wheezing used for research, and definitions vary by study.
The most common definition of wheezing is the definition used by the International Study of
Asthma and Allergies in Childhood (ISAAC) which defines current wheezing as: “wheezing or
whistling in the chest in the last 12 months?”2. Studies that use the ISAAC definition of current
wheezing are known to report significantly higher prevalences for wheezing than non-ISAAC
studies3, this is likely due to the ISAAC definition of current wheezing including any wheezing
recalled in the preceding 12 months of the study.
Wheezing is common in both adults and children, by six years of age approximately 50% of
children in high-income countries will have experienced at least one episode of wheezing in
their life4. The regional point prevalence of childhood wheezing varies greatly based on the
country and age group that was surveyed, from 2.4% in Jodhpur, India to 37.6% in Costa Rica
amongst six to seven-year-old children and from 0.8% in Tibet, China to 32.6% in Wellington,
New Zealand in thirteen to fourteen-year-old children5. Although the prevalence of wheezing
is similar in adults and children, the medical burden of wheeze disproportionately affects young
children.
The overall global impact of wheeze is difficult to determine given that wheezing is associated
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with respiratory morbidity in children but is also closely linked to reduced lung function and the
development of asthma in later life6,7. Wheezing negatively impacts health in both the short and
long-term, it is also a considerable financial burden. Not only do the families of children have to
pay for care for each individual episode of wheezing, but additional costs such as time and wage
loss when caring for the sick child are also significant contributors to the financial burden of
wheezing. It is estimated that the economic cost of childhood wheezing for a single year in the
United Kingdom was 53 million GBP in 1998, roughly 90 million GBP per year when adjusted
for inflation8.
Childhood Wheeze Phenotypes
Along with the difficulty in measuring and classifying wheezing as an outcome, determining
the risk factors for wheezing is complicated due to the fact that wheezing in young children is
not a single disorder but a heterogeneous condition with distinct phenotypes and risk factors
that vary as children age. Although children may wheeze for a variety of different reasons
at any given age, the majority of early childhood wheezing is associated with respiratory tract
infections (RTIs), and late-onset wheezing and asthma associatedwith allergy and atopic disease.
Both genetic and environmental risk factors play critical roles in the development of childhood
wheeze.
Seminal early work on wheezing and asthma in young children in the Tuscon Children’s Res-
piratory Study, a birth cohort in the United States, found that children with wheezing can be
broadly classified into four heterogeneous wheeze phenotypes based on the age at which the
child first wheezed as well as whether or not the wheezing persisted throughout early child-
hood4. In this description children are classified as those with no wheeze at three and six years
of life; those that have at least one episode of wheezing in the first three years of life but not
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at six years (transient wheeze); those who had no episodes of wheezing in the first three years
of life but who had wheeze at by the age of six (late-onset wheeze) and those who had at least
one episode of wheezing in the first three years of life and had wheezing at six years of age
(persistent wheeze)4.
The childhood wheeze phenotypes described by Martinez, Wright, et al. [4] were further ex-
panded upon in a study by Lodge, Zaloumis, et al. [9]. This study followed 620 children at
high-risk for allergy from birth to the age of seven, with a final follow-up at twelve years of
age. The study used latent class analysis (LCA) to detect subgroups of wheezing in the chil-
dren. The study found that the children could be classified into one of five wheeze phenotypes:
never/infrequent wheeze, early transient wheeze, early persistent wheeze, intermediate-onset
wheeze, and late-onset wheeze. Early transient wheeze appeared in the first twelve months of
life and resolved permanently at around three years. Early persistent wheeze appeared in the first
6 months of life, intermediate-onset wheeze emerged at around eighteen months, and late-onset
wheeze occurred after the age of four.
Given the above phenotypes for wheeze and the periods in a child’s life when they are most
prevalent, childhood wheezing can be broadly described as occurring in three distinct age ranges
with risk factors that vary based on the age: the first three years of childhood; middle and late
childhood, from the age of four to ten, and early adolescence.
Wheeze in the First Three years of Life
The majority of children who experience wheezing in the first three years of life are classified
as transient wheezers, as they do not experience wheezing after the first three years of life4. The
Tucson Children’s Respiratory Study10, a study of 826 new-born infants in the United States
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found that one-third of all children under three years of age had wheezed in conjunction with
a lower respiratory tract illness. However, 60% of those children had stopped wheezing by the
age of six4. Similarly, in Australia, 73% of children who wheezed in the first six months of life
did not wheeze three years later11.
Children with transient wheeze are believed to have smaller airways than children who never
wheeze, and it is the reduced airway calibre that predisposes children to obstructive respiratory
tract infections and wheezing during early childhood12. As the children age, the predisposition
for wheezing is mitigated by the increase in airway size of older children. The majority of
children experience transient wheezing in early life and are then considered symptom-free in
later life.
For example, young children with respiratory syncytial virus (RSV) were 3.2 times more likely
to have zero to three episodes of wheezing in the past year and 4.3 times more likely to have
more than three episodes of wheezing in the past year when compared to children with no RSV.
However, as airway size increased with age the risk of wheezing decreased and by age thir-
teen there was no significant difference in the risk of wheezing between children with RSV and
children without RSV in the first three years of life7,13. The association between wheezing and
respiratory tract infections was not unique to RSV, although RSV is the most commonly diag-
nosed respiratory tract infection. The presence of any lower respiratory tract infection (LRTI)
was associated with a three-fold increase in the risk of transient wheezing. Furthermore, the
risk of wheezing was 3.7 times higher in children in the lowest tertile of total respiratory con-
ductance (a measure of overall respiratory function) prior to the first episode of wheezing14,
indicating that diminished lung function may not be a consequence of respiratory infections but
was present prior to any respiratory tract infections.
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Given that transient wheezing is closely associated with respiratory tract infections, many of the
risk factors for respiratory infection in young children are also risk factors for transient wheez-
ing. For example, there is a well-documented association between respiratory tract infections
and exposure to other children, either siblings or at a day-care, in early life15–17. Similarly,
exposure to other children is also a risk factor for transient wheeze17–19. Other environmental
risk factors for respiratory infections and transient wheezing include the season of birth11,20,21
and length and type of breastfeeding11,20,22. Exposure to maternal smoking is also a critical risk
factor in the development of transient wheezing and many studies of childhood wheeze that
have included it as a covariate have found that it significantly increases the risk of developing
wheezing4,11,21,23–25.
There is also evidence that genetic factors may predispose young children to respiratory infec-
tions and transient wheeze. Initially, male children in the United States were believed to have a
higher risk of wheezing in the first three years of life21, however later work on children of the
same age has found no increase in transient wheezing amongst males, sex only increased the
risk of late-onset and persistent wheezing4. Furthermore, another study that investigated sex as
a risk factor found no significant difference in the risk of wheezing between the sexes, however,
the study included only 132 infants with wheeze and thus may be underpowered for the analysis
that was conducted26.
Wheeze in Middle and Late Childhood
Although the majority of children wheeze only during early childhood and never again, a small
subset of children wheeze persistently throughout childhood. Similarly, there is a separate subset
of children who do not experience wheezing in the first three years of life but develop wheezing
after the age of three, this wheeze phenotype is known as late-onset wheeze. The majority of
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children who wheeze after the first three years of life are classified as having either late-onset or
persistent wheeze, by the age of ten persistent wheezing is the most common wheeze phenotype.
Although the two wheeze phenotypes are distinct they share many of the same risk factors. A
combination of genetic factors and exposure to adverse events postnatally predispose children
to both persistent and late-onset wheezing in middle childhood and beyond11.
The differences in lung function between transient wheeze and other wheeze phenotypes per-
sist beyond early childhood. Lodge, Lowe, et al. [27] demonstrated that all childhood wheeze
phenotypes, except transient wheeze, were associated with lower lung function growth through-
out early childhood and continuing into late adolescence when compared to children who had
never wheezed. Furthermore, all wheeze phenotypes, except transient wheezing, were associ-
ated with an increased risk of current wheezing at twelve years of age in children in the United
States9.
Many of the risk factors for late-onset and persistent wheezing are related to allergic sensitization
and atopic disease. Asthma and other atopic diseases are known to commonly co-occur in both
adults and children28, and are also key risk factors for the development of persistent or late-
onset wheezing in middle and late childhood26,29–31. For example, children born to mothers with
atopy were almost twice as likely to suffer from persistent wheezing than those born to mothers
without atopy, if the mother had both asthma and eczema the child was almost three times as
likely to develop persistent wheezing before the age of seven25.
Parental asthma is also a strong risk factor for the development of wheezing32,33. However, when
the risk factors for each wheeze phenotype were considered independently maternal asthma was
only found to significantly increase the risk of persistent and late-onset wheezing and not tran-
sient wheezing4. Work done on wheezing since has strengthened the evidence for a strong as-
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sociation between maternal asthma and various forms of childhood wheeze, regardless of the
cultural setting of the study or participant socio-economic status11,20,23,25,31,34,35. Only one of
the studies classified wheezing into separate phenotypes. The study found that the proportion
of children who wheeze persistently and had mothers with a history of asthma was double the
proportion of those who wheeze persistently but did not have a maternal history of asthma. It
is difficult to estimate the effect of maternal and paternal asthma independently, as much of
the work on childhood wheezing either measures maternal asthma alone or creates a composite
measure of “parental history of asthma”. However, the study found that maternal, but not pater-
nal asthma was associated with an increased risk of persistent wheezing. However, asthma in
both parents has been associated with an increased risk of late-onset wheezing11.
The association between childhood asthma and allergic sensitisation has not been as well studied
as parental atopy, given the difficulty of assessing whether a young child is allergic or not.
However, childhood asthma and atopy have been consistently implicated as important predictors
of late-onset or persistent wheezing when they have been studied4,32,36,37. The prevalence of
asthma in late childhood and adulthood is strongly associated with serum IgE levels38. However,
one study found no association between serum IgE levels at birth and wheezing shortly after
birth39. Although the results appear contradictory, Martinez, Wright, et al. [4] found that total
IgE at birth was not predictive of wheeze phenotype, but by nine months, persistent wheezers
had significantly higher IgE compared to the other wheeze phenotypes. This suggests that those
with persistent wheezing may be genetically predisposed to developing a different immunologic
response to exposures and events in the first few months of life.
Initially, it was believed that LRTIs early in childhood were associated with an increased risk
of developing respiratory symptoms, including wheezing, in later childhood and early adoles-
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cence40. It was believed that LRTIs predisposed children to asthma by damaging their airways
in early life. However, the literature on the relationship between LRTIs in early life and devel-
opment of respiratory symptoms in later life is contradictory41. Stein et al. [13] investigated the
relationship between RSV infection in the first three years of life and wheezing at the age of
thirteen and found that RSV infection by the age of three was associated with an increased risk
of wheezing at age six. However, by the age of thirteen, there was no association between RSV
infection in the first three years of life and wheezing. Furthermore, there was no association
between RSV infection and atopy later in life. Later research suggests that RSV infection may
be associated with recurrent wheezing in later life however more research is needed42.
The epidemiology of late-onset wheeze is made more complicated by the bimodal effect of
some of the risk factors for wheezing. For example, exposure to other children in early life is
associated with an increased risk of respiratory infection and wheezing17–19, however, exposure
to other children in early life was also found to be associated with lower levels of asthma in
thirteen-year-old children18. It is thought that exposure to microbes in early childhood may
provide protection against atopic disease in later life.
Need for Further Research
Many studies have investigated the epidemiology of childhood wheezing, however, it is impor-
tant to note the limitations of the current literature. Although some work on wheeze has been
conducted in Brazil and Ecuador43–45, the majority of the literature on childhood wheezing has
been conducted in high-income countries (HIC), there is a lack of studies investigating childhood
wheezing in low andmiddle-income countries (LMIC) particularly in an African context. Africa
and South Africa are of interest given the ever-increasing prevalence of asthma and wheezing
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in South African children46.
Childhood wheezing is a fundamentally longitudinal process, with risk factors that can vary
dramatically based on the age of the child, and the individual child’s disease history. Although
much of the literature on childhood wheezing utilises longitudinal data from prospective birth
cohorts, the methods used to analyse the data generally only make use of a cross-sectional snap-
shot of the data. The most common method of analysis for childhood wheezing in the literature
was a multivariable logistic regression model of the last year of the study only (current wheez-
ing defined as any wheezing in the past twelve months), only two of the studies included in
this review utilised methods that accounted for the repeated measures of longitudinal data18,24.
By using only the final twelve months of any given study much of the data collected in the
prospective birth cohort is ignored. Furthermore, by using only a snapshot of the data studies
may not capture information about risk factors that have varied as the child ages. This effect
is of particular concern when young children are the focus of the study, given the rapid growth
and change in risk factors that occur in young children. This may lead to misclassification of
the child’s wheeze phenotype and their potential risk factors. Further research that takes into ac-
count the longitudinal nature of wheeze progression and the recurrent measures inherent in such
data sources is necessary to provide an accurate assessment of the epidemiology of wheezing in
early childhood.
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Abstract
Background: Childhood wheezing is associated with a range of morbidities including de-
creased lung function in later life. To date, the recurrent nature of childhood wheeze has not
been examined in low- and middle-income countries. The objective of this study is to utilise
multi-state models to estimate the rate of transition between various states of childhood wheeze
and the effect of risk factors on those transitions in the context of a low- and middle-income
country.
Methods: Longitudinal data are from 1086 children aged zero to three years, living in two
peri-urban communities in South Africa collected as part of the Drakenstein Child Health Study.
Transition intensities between wheeze states were estimated using discrete timemulti-state mod-
els. The effects of risk factors on transition intensities were estimated using multivariable pro-
portional hazards models.
Results: Transition from theNoWheeze state to theWheeze state (0.00043) was equally likely
as a transition to the LRTI-associated wheeze (0.0003). The transition from LRTI-associated
Wheeze to Wheeze (0.002) was twice as likely as a transition from Wheeze to LRTI-associated
Wheeze (0.00087). Male children were at significantly higher risk of having LRTI-associated
wheeze as the first wheeze episode and at significantly higher risk of recurrent wheeze. Children
exposed to prenatal maternal smoking had significantly increased risk of transition to the wheeze
state compared to children not exposed to maternal smoking.
Conclusions: Multi-state models offer a novel way to study the progress of recurrent child-
hood wheeze with interval-censored data. Multi-state models for wheeze provide compara-
ble results to traditional survival analysis while utilising data beyond the first occurrence of
wheeze.
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Key Messages: Multi-state models provide a novel framework for the analysis of childhood
wheeze that deals with recurrent events and interval-censored data while providing estimates
for risk factors comparable with traditional methods of analysis.
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Introduction
Wheezing is defined as a continuous, coarse, whistling sound produced during breathing1. Wheez-
ing is caused by obstructed respiratory passages, however, diagnosis is challenging givenwheez-
ing is a symptom of many related respiratory diseases, such as pneumonia. Childhood wheezing
is a common occurrence, by the age of six approximately 50% of children in high-income coun-
tries will have experienced one or more episodes of wheezing in their life2. Furthermore, child-
hood wheeze is closely associated with reduced lung function and the development of asthma
in later life3,4. Wheezing is not only a significant burden on the health of individual children
but also places a significant burden on health systems, for example, it is estimated that the eco-
nomic cost of childhood wheezing for a single year in the United Kingdom was 53 million GBP
in 1998, approximately 90 million GBP per year when adjusted for inflation5. The prevalence of
childhood wheezing and asthma has remained relatively constant in Europe, however, the preva-
lence of wheezing and asthma in Africa is increasing. The 12-month prevalence of wheezing
in Africa in children aged six to seven is estimated to be 5.6%, and the 12-month prevalence of
wheeze in children aged 13 to 14 is estimated to be 13.4%6. The estimated 12-month prevalence
of wheezing in children aged thirteen to fourteen in Cape Town is higher than both the African
and global estimates, with 20.3% of children experiencing wheezing7.
The prevalence of wheeze and asthma are increasing in low- and middle-income countries
(LMICs), although some work on wheeze has been conducted in Brazil and Ecuador8–10, there
is a paucity of research in these contexts, as most research has been conducted in high-income
countries (HICs). Furthermore, although many wheeze studies are positioned in prospective
birth cohort studies the most common method for the analysis of childhood wheeze is mul-
tivariable logistic regression investigating the outcome (typically “any episodes of wheeze in
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the preceding 12 months”) in a cross-sectional manner at a single time-point in the study. This
study investigates the use of multi-state models to estimate the transition probability among var-
ious childhood wheeze states; no wheeze, wheeze, and lower respiratory tract (LRTI)-associated
wheeze in a birth cohort of children followed up to three years of age. We also investigated the
association between possible risk factors for childhood wheeze (sex, exposure to other children
at home, exposure to maternal smoking, maternal history of asthma and season of birth), on the
estimated transition intensities while accounting for the time-varying nature of covariates and
the interval censored nature of the data.
Participants and Methods
Study Design
This study is a secondary analysis of data collected in a prospective birth cohort of mother-
infant pairs enrolled in the Drakenstein Child Health Study (DCHS)11. The DCHS is a multi-
disciplinary prospective birth cohort that aims to investigate the epidemiology, aetiology and
long-term impact of early LRTI on child health in a LMIC. The protocol of the parent study has
been described in detail elsewhere11. The study population for this analysis were children born
to mothers in the Drakenstein area that made use of one of the two primary care clinics, TC
Newman and Clinic and Mbekweni Clinic and who intended to remain in the area for at least a
full year following enrolment. Study participants were located in the Drakenstein area in Paarl,
the area has a population of approximately 200 000 people. The population is considered stable
with little immigration or emigration11.
The majority of the Drakenstein community members are of low socio-economic status and live
in informal housing or crowded conditions. There is a high prevalence of various poverty-related
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exposures, such as tobacco smoke exposure, alcohol misuse, and malnutrition11. More than 90%
of the population made use of the freely available public healthcare system. The public health
system in the Drakenstein area is comprised of 23 primary care clinics and one hospital, Paarl
Hospital, where all births and hospital care occurred11.
Data Collection
Socio-economic andmedicalmaternal questionnaireswere administered at antenatal visits. Child
clinical and respiratory symptom questionnaires were completed at hospital visits and at routine
study visits, which occurred at 6, 10 and 14 weeks, and 6, 9, 18, 30, 36, 42, 54 and 60 months
as well as ad hoc visits for LRTI11. Active surveillance for LRTI was performed by the nurses
at the study sites. Study nurses were trained to examine the respiratory health of children at
sick visits. Measurements of LRTI included ambulatory and hospitalised pneumonia cases, as
defined by World Health Organization (WHO) criteria. The current study reports on the first
three years (36 months) of follow-up for each infant. Unattended visits were documented as
missing but children were retained in intervals if they attended future visits.
Measures
Childhood wheezing was assessed in two distinct manners. Firstly, wheezing was identified by
parental report as a positive answer to the question “Has your child had a wheezing or whistling
noise coming from his/her chest in the past 6 months?”. Secondly, trained healthcare workers
recorded if a child had wheezing evident while present at a study or sick visit. Identification
of wheezing could occur at planned study visits or at unscheduled visits for LRTI. Recurrent
wheezing was defined as two or more episodes of wheezing, either parental report or healthcare
worker observed, within a twelve month period.
35 of 73
Children who had no episodes of wheezing for the entire period of follow-up were classified
as having never wheezed. Children who wheezed only once or had episodes of wheezing that
were more than 12 months apart were classified as infrequent or transient wheezers. Similarly,
children who had two or more episodes of wheezing in a 12-month period were classified as
having recurrent wheezing. The time to first wheezing was the time in days from birth until the
first episode of wheezing. The time to recurrent wheezing was the time in days from birth until
the second episode of wheezing.
Statistical Analysis
All analyses were conducted in R (version 3.5.2)12. Descriptive statistics were presented as
medians, interquartile ranges and frequencies (proportions), as appropriate. Survival curves for
time to first wheeze and time to first recurrent wheezing were estimated using the product-limit
estimator. Cox Proportional Hazards regression13, including all potential confounding variables
(infant sex, exposure to maternal smoke, exposure to other children and hospitalization), was
used to estimate the association of potential risk factors with the time to first wheezing, as well as
the time to first recurrent wheezing. The proportionality of hazards in the Cox model was inves-
tigated by plotting scaled Schoenfeld residuals of each covariate against survival time14.
Multi-state Models
Multi-state models are a useful framework for modelling the progression of individuals through
defined disease states, particularly when observations are captured at arbitrary timepoints rel-
ative to disease progression15. Therefore, a multi-state model was constructed to estimate the
transition probabilities between pre-defined childhood wheeze states, as well as the effect of
various risk factors (infant sex, exposure to maternal smoke, and exposure to other children) on
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Figure 1: Diagram of the multi-state model used to estimate transition probabilities for child-
hood wheezing and LRTI-associated wheezing.
the transition probabilities. Given that follow-up in the DCHS begins at birth, all infants were
assumed to be in the no wheeze state at t = 0.
The multi-state model allowed four possible transitions: 1) from “never wheeze” to “wheeze” or
from 2) “never wheeze” to “LRTI-associated wheeze” or from 3) “wheeze” to “LRTI-associated
wheeze” and from 4) “LRTI-associated wheeze” to “wheeze” (Fig. 1). Themulti-state processes
described abovewere all assumed to beMarkovian, that is that future transition depended only on
the currently occupied state. Although the multi-state processes were assumed to be Markovian,
the risk of wheezing is known to decrease as infants age, with children younger than six months
at greater risk of wheezing than older children16. Given that the risk of wheezing decreases
with age, the transition intensities for the multi-state model in this study were assumed to have
piecewise constant intensities. Namely, the transition intensities remained constant within each
defined time period (0 - 180 days, 180 - 336 days, 336 - 728 days, and 728 - 1100 days), but
could differ between time periods. Observation times of individuals were assumed to be non-
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informative and interval censored with respect to disease progression. Covariate effects were
estimated using a proportional hazards model for each transition17. All multi-state analyses were
conducted using the msm package18 for R12. Model assessment for panel-observed multi-state
models is not straightforward due to transition times between adjacent states being unknown, it is
further complicated by the interval censored nature of the data present in this study19. Therefore,
in order to assess model fit in this study the expected prevalences in each state were compared
to the empirical prevalences at all time points.
Ethical Approval
The DCHS received approval from the Ethics Committee of the Faculty of Health Sciences,
University of Cape Town (HREC: 401/2009), as well as StellenboschUniversity and theWestern
Cape Provincial Research committee. The current study was approved by the Ethics Committee
of the Faculty of Health Sciences, University of Cape Town (HREC: 805/2018).
Results
In total 1086 infants were considered for this study (Fig. A1), the median follow-up time at the
end of the study period was 913 days (784.25 - 923.75). Given the differing enrolment dates of
infants into the DCHS, at the time of data extraction not all children in the DCHS had reached
three years of age. Baseline demographic and clinical characteristics are presented in Table 1.
An equal number of infants from both sexes were present in the study. The median birthweight
for infants in the study was 3.0799999kg. A maternal history of asthma was rare in this cohort,
only 1% of mothers in the study had a history of asthma. Approximately 23 of the mothers in
the study self-reported smoking during pregnancy.
38 of 73
Table 1: Descriptive statistics [median (IQR) or n (%)] for children with transient or recurrent wheeze in the Drak-
enstein Child Health Study.
Characteristics Overall
(n = 1086)
Never/Infrequent Wheeze
(n = 859)
Recurrent Wheeze
(n = 227)
Age at First Wheeze (in days)1 180 (80.25 - 390.25) 255 (100 - 547) 130 (70 - 275.5)
Birth Weight (in kg) 3.08 (2.71 - 3.42) 3.12 (2.75 - 3.44) 3.04 (2.63 - 3.38)
Number of Children at Home 3 (3 - 4) 3 (3 - 4) 3 (3 - 4)
Sex
Male 564 (51.93%) 420 (48.89%) 144 (63.44%)
Female 522 (48.07%) 439 (51.11%) 83 (36.56%)
Prenatal Maternal Smoking
Yes 251 (23.11%) 181 (21.07%) 70 (30.84%)
No 822 (75.69%) 669 (77.88%) 153 (67.4%)
Unknown 13 (1.2%) 9 (1.05%) 4 (1.76%)
Maternal History of Asthma
Yes 11 (1.01%) 7 (0.81%) 4 (1.76%)
No 1068 (98.34%) 847 (98.6%) 221 (97.36%)
Unknown 7 (0.64%) 5 (0.58%) 2 (0.88%)
Season of Birth
Autumn (1 March – 31 May) 268 (24.68%) 189 (22%) 79 (34.8%)
Winter (1 June – 31 August) 288 (26.52%) 237 (27.59%) 51 (22.47%)
Spring (1 September – 30 November) 256 (23.57%) 214 (24.91%) 42 (18.5%)
Summer (1 December – 28 February) 274 (25.23%) 219 (25.49%) 55 (24.23%)
1 Amongst those who experienced wheeze.
Composite wheezing was defined as either parentally reported or staff diagnosed wheezing at a
given visit. A total of 951 episodes of wheezing were recorded in the 36 months of follow-up
time reported on in this study, 610 (56%)children did not experience any episodes of wheezing.
The incidence of wheezing in the cohort for the follow-up time reported on in this study was
0.114 episodes per child-year. Of the 951 episodes of wheezing, 650 (68.35%) were parentally
reported, and 489 (51.42%)were diagnosed by study staff at a study visit. 188 (19.77%) episodes
of wheezing were identified by both parental report and observed by study staff. The period
prevalence of childhood wheezing in the first 36 months for the composite wheezing outcome
was 43.8% (95% CI: 40.9% - 46.8%). The period prevalence of parentally-reported wheezing,
for the same period, was 36.3% (95% CI: 33.4% - 39.1%), and the period prevalence of staff-
diagnosed wheezing was 26.6% (95% CI: 24% - 29.2%).
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The number of composite wheezing events in the first six months of follow-up time was 258,
and the period prevalence of the composite wheezing outcome for the first six months only
was 23.8% (95% CI: 21.2% - 26.3%). The period prevalence of parentally-reported and staff-
reported wheezing was 16.7% (95% CI: 14.5% - 18.9%) and 13.5% (95% CI: 11.5% - 15.6%)
respectively. Of the 1086 children in the study, 227 (20.9%) experienced more than one episode
of wheezing in the three years of follow-up. The majority of children who experienced recurrent
wheeze (63%) were male.
The median time to first wheezing episode was 946 days (95% CI: 916 - 1018 days), however,
the median time to recurrent wheezing was not reached in the three years of follow-up (Fig. 2) as
only 227 (20.9%) children had a recurrent wheezing episode. Male children had a significantly
lowermedian time to first wheezing episode (916 days; 95%CI: 752 - 1001) than female children
(1018 days; 95% CI: 924 - NA). However, given that so few individuals had recurrent episodes
of wheezing the estimate for median survival time for recurrent wheeze is outside the follow-up
window in this study.
In multivariable Cox regression analysis for time to first wheezing, no risk factors were associ-
ated with a significantly increased hazard of wheeze. While not significant, male children (HR
= 1.16; 95% CI: 0.96 - 1.4), hospitalization for a pneumonia episode (HR = 1.22; 95% CI: 0.89
- 1.67), or exposure to other children at home (HR = 1.03; 95% CI: 0.95 - 1.11) were all asso-
ciated with an increased hazard of wheezing. Furthermore, while not significant, the season of
birth (Spring, Summer andWinter) was associated with a decreased hazard of wheezing relative
to birth in Autumn. The results of the multivariable Cox regression for time to first recurrent
wheezing were similar to the results for time to first wheeze episode in both magnitude and
direction (Table A1). However, exposure to other children in the home was associated with a
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significantly increased hazard of recurrent wheezing (HR = 1.19; 95% CI: 1.07 - 1.32). Diag-
nostic for both time to first wheeze and time to first recurrent wheeze Cox proportional hazards
models indicate that the proportional hazards assumption had not been violated.
| | ||||||||||||||||||||||| ||||||| | | |||| | |||||||| ||| | |||||||||| | || ||||||| ||||||||||||| | ||||||||||||||||||||||||||||||||||||||||||||||||
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Figure 2: Kaplan-Meier Curve for time to first wheezing episode and first recurrent wheezing
episode
Multi-state Model
The number of transitions between consecutive observed states for all states over the entire
three year period of follow-up is presented in Table 2. There were a total of 672 transitions into
adjacent states. The primary results of the multi-state analysis, using composite wheezing as the
outcome, are displayed in Table 3, the maximum likelihood estimate (MLE) and corresponding
95% confidence intervals at the mean value for all covariates for each allowed transition are
presented. For categorical variables, the mean of the 0/1 dummy variable for each factor level
was used, representing an average over all values in the data, rather than a specific factor level.
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The multi-state analysis was repeated for the two other definitions of wheeze (parental report
and staff diagnosed; Appendix D), the covariate effects on transitions were similar to those
reported for the composite wheezing endpoint. However, the confidence intervals were wider
and transition intensities between states were significantly lower given the reduced number of
transitions into each state.
Table 2: The number of transitions between each consecutive state in the LRTI-associated
wheeze multi-state model for the full duration of follow-up.
No Wheeze Wheeze LRTI-Wheeze
No Wheeze 4889 243 170
Wheeze 0 1237 110
LRTI-Wheeze 0 149 849
Transition from the No Wheeze (State 1)
Children who had never wheezed were equally likely to transition to having wheeze (0.0004) as
they were to transition to LRTI-associated wheeze (0.0003). The probability that an individual
who was in the no wheeze state at six-months would transition to the wheeze state by thirty-six
months was 0.296 (95 % CI: 0.256 - 0.352), and the probability an individual would transition
from No Wheeze to the LRTI-associated wheeze state by the end of the same time period was
0.101 (95 % CI: 0.077 - 0.14). The transition probabilities estimate the relative chance that an
individual transitions from a given state to another state within the defined time period.
The hazard ratios for each transition of the multi-state model analysed in this study are presented
in Table 4. Male children were more likely to transition to the Wheeze state (HR = 1.029; 95%
CI: 0.775 - 1.365) and to the LRTI-associatedWheeze state (HR = 1.766; 95%CI: 1.265 - 2.465).
Similarly, children exposed to prenatal maternal smoking were more likely to transition from
the no wheeze state to the wheeze state (HR = 1.598; 95% CI: 1.173 - 2.179). The transition
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intensity for all transitions out of the wheeze state decreased over time, after the first six months
the baseline transition intensity for the no wheeze to wheeze transition was less than half the
initial transition intensity (HR = 0.451; 95% CI: 0.31 - 0.656).
Table 3: Estimated baseline transition intensity matrix for the Wheeze and LRTI-associated
Wheeze multi-state model in the DCHS.
State Wheeze LRTI-Wheeze
MLE 95% CI MLE 95% CI
No Wheeze 0.00043 0.00036; 0.0005 0.0003 0.00025; 0.00037
Wheeze 0a 0.00087 0.00069; 0.00087
LRTI-Wheeze 0.002 0.0016; 0.0025 0a
a Transition intensities were defined as zero in the multi-state model.
Transition from Wheeze (State 2)
The transition intensity for the transition from the wheeze state to the LRTI-associated wheeze
state was 0.00087, approximately half the transition intensity for the LRTI-associated wheeze
to wheeze transition (0.002). The six-month transition probability of moving from the Wheeze
state to the LRTI-associated wheeze state was 0.181. Similarly, the probability an individual
in the wheeze state at six months would be observed in the LRTI-associated wheeze state at 36
months was 0.227.
All transition intensities from the wheeze state decreased relative to the first time period (0 to 180
days). Male childrenwere approximately twice as likely to transition from thewheeze state to the
LRTI-associated wheeze state (HR = 1.79; 95% CI: 1.17 - 2.75) than female children. Children
exposed to prenatal maternal smoking were more likely to transition from the wheeze state to
the LRTI-associated wheeze state (HR = 1.31; 95% CI: 0.84 - 2.04), however, the increase was
not statistically significant (Table 4).
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Transition from LRTI-associated wheeze (State 3)
The transition intensity for the transition to the non-LRTI associated wheeze state was 0.002,
approximately double the transition intensity for the transition from thewheeze state to the LRTI-
associated wheeze state (0.00087). The transition probability for the 0 - 180 day time period for
transition to the wheeze state was 0.642. Similarly, the transition probability for the 180 - 1100
day period for the same transition was 0.638. The transition intensity for all transitions out of the
LRTI-associated wheeze state decreased significantly over the three year period of follow-up.
Male children and children who were exposed to prenatal maternal smoking had a significantly
increased hazard of transition from the LRTI-associated wheeze state (Table 4).
Model fit was assessed graphically by plotting the observed prevalence for each state against
the expected prevalence for each state (Fig. A2). Model fit was generally acceptable, how-
ever, observed and expected prevalence deviated sharply for follow-up times greater than 1000
days.
Discussion
This study explored a novel application of multi-state Markov models for interval-censored ob-
servations to describe the childhood wheeze disease process from the ages of zero to three years,
within the context of a low- and middle-income setting The period prevalence reported in this
study is within the range of similar studies on childhood wheezing2,20. The period prevalence
of healthcare worker ascertained wheezing (26.6%) was lower than both parentally-reported
(36.3%) and composite wheezing (43.8%) likely due to the manner in which staff-reported
wheezing was assessed. Study-staff only reported wheezing if it was present at a given study
visit, whereas parentally-reported wheeze and composite wheeze reporting included the recol-
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lection of the preceding months prior to a study or sick visit.
None of the known risk factors for childhood wheezing included in the multivariable Cox model
for time to first wheezing were significantly associated with an increased risk of wheezing. For
example, prenatal exposure to maternal smoking is known to be associated with an increased
risk of childhood wheezing2,16,21,22. Although children exposed to prenatal maternal smoking
did have a 1.08 (95% CI: 0.87 - 1.34) times higher hazard of wheezing it was not statistically
significant. Similarly, the only risk factor associated with a significantly increased hazard of re-
current wheezing in these models was exposure to other children at home. One of the limitations
of Cox models and other methods that do not account for the recurrent nature of wheezing is that
data after the first event is not included in the analysis. This can be particularly problematic for
childhood wheezing given that the risk factors for the first wheezing episode may be different
from subsequent wheezing events16.
Themulti-state model in this study allowed for the inclusion of individuals with recurrent wheez-
ing. Although, the majority of children had one or fewer episodes of wheezing in the three years
of follow-up, by accounting for children with recurrent wheezing a further 259 transitions were
included in the multi-state analysis. The risk of transition into any wheeze state decreased sig-
nificantly as children aged, the first six months of life had the greatest transition intensity for
all transitions in the multi-state model. These results support findings from several studies, that
used cross-sectional methods of analysis, on the age-related risk of wheezing3,16,22,23 and extend
them into an LMIC context.
There was no significant difference between the sexes for transition into the wheeze state. How-
ever, male children were significantly more likely to transition into the LRTI-associated wheeze
state from any state. Furthermore, male children were more likely to have more than one episode
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of wheezing. The results support findings from similar studies in HICs2,24,25. It is believed that
the increased risk of wheeze for male children is likely a combination of an inheritable predis-
position to wheezing26 and biomechanical differences in lung morphology between male and
female children27. It is reasonable to believe that these risk factors would remain consistent
regardless of setting.
There is a well-known association between maternal smoking and wheeze in children2,16,21,28,
however, the associations in this study were not consistent. Maternal smoking was associated
with a significantly increased risk of transition into the wheeze state from any state. Mater-
nal smoking was not associated with a significantly increased risk of transition into the LRTI-
associated wheeze state. Given the strength of the evidence for an association between maternal
smoking and wheezing, and maternal smoking and LRTI, it is likely that the discrepancy be-
tween the two transitions in this study is a result of the smaller number of transitions into the
LRTI-associated wheeze state which may have led to reduced power. Another possible expla-
nation for the discrepancy is that in this study maternal smoking was measured via maternal
self-report and that this measure may under-represent true smoking exposure given the stigma
associated with maternal smoking during pregnancy.
Although therewere no significant associations detected by the Cox Proportional Hazardsmodel,
the direction of effect for all of the risk factors that were included in both the Cox regression
model and the multi-state model was the same. However, the multi-state model made use of
all of the wheezing events (944 events), whereas the Cox Proportional Hazards models for time
to first wheeze and time to recurrent wheezing included only 450 and 254 events respectively.
Furthermore, unlike Cox models, multi-state models provide an easily extensible framework,
that can be used to deal with covariates that differ for different transitions or events.
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This study has several strengths and limitations. A major strength of the analysis in this study
was the use of prospectively collected longitudinal data and an appropriate analysis method that
allowed for recurrent events and time-varying exposures, which to the author’s knowledge is the
first use of multi-state models for the analysis of childhood wheezing in the context of an LMIC.
However, parametric multi-state Markov models make strong assumptions about the underlying
disease process (“the memorylessness property” and constant baseline transitions) that may not
be suitable for all disease processes. Multi-state models can be extended to deal with violations
of these assumptions, for example, piecewise models, as used in this study, can be fitted if it is
believed that baseline transition intensities differ over the entire study period but remain constant
for shorter time periods. Another important limitation of this study is that the number of children
that transitioned into some states was lowwhich may lead to a lack of statistical power. A further
limitation of this study is that a narrow set of prespecified covariates were included in the multi-
state model. Furthermore, it is important to note that the parentally reported wheeze outcome
is determined by parental recall, and parents may be more likely to recall wheezing symptoms
if their children were ill at some point in the study. The composite wheezing outcome may
be similarly biased given it is a composite of parental recall and healthcare worker observed
wheeze.
Conclusion
This study has shown a novel application of multi-state Markov models for the analysis of
childhood wheeze in a South African context. The multi-state model successfully predicted
the progress of childhood wheezing and produced results consistent with existing literature on
childhoodwheezingwhile accounting for the recurrent nature of wheezing and interval-censored
observations. However, further research should investigate the use of more complex multi-state
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models to account for the differing wheeze phenotypes and their associated risk factors.
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A Supplementary figures/tables included in Manuscript
Table A1: Relative risks of wheeze and recurrent wheeze amongst children aged zero to three
years in the DCHS.
Variable First Wheeze First Recurrent WheezeHR 95% CI HR 95% CI
Exposure to other children
at home 1.03 0.95 - 1.11 1.19 1.07 - 1.32
Sex
Male 1.16 0.96 - 1.4 1.23 0.95 - 1.6
Female Reference
Prenatal Maternal Smoking
Yes 1.08 0.87 - 1.34 1.2 0.91 - 1.59
No Reference
Season of Birth
Winter (1 June – 31 August) 0.83 0.64 - 1.08 0.75 0.53 - 1.06
Spring (1 September – 30 November) 0.75 0.58 - 0.98 0.69 0.49 - 0.99
Summer (1 December – 28 February) 0.9 0.7 - 1.16 0.7 0.49 - 0.98
Autumn (1 March – 31 May) Reference
Hospitalization for Pneumonia
Hospitalized 1.22 0.89 - 1.67 1.19 0.76 - 1.85
Ambulatory Reference
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Figure A1: Consort diagram of enrolment, inclusion and exclusion criteria.
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Figure A2: Observed vs expected prevalence for each state in the multi-state model at each
time point.
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Figure D3: Model schematic for simple uni-directional three-state model of childhood wheeze
Never Wheeze Wheeze Recurrent Wheeze
λ12 λ23
Table D2: The number of transitions between each consecutive state for simple mutli-state
model for the full duration of follow-up.
Model 1: Unidirectional Three-State Model
Never Wheeze Ever Wheeze Recurrent Wheeze
Never Wheeze 4889 413 0
Ever Wheeze 0 1173 227
Recurrent Wheeze 0 0 945
D Appendices to the Thesis
All analysis that were completed as part of the MPH, but were not included in the manuscript
portion are presented here for completeness.
Table D3: Estimated baseline transition intensity matrix, with covariates set at their mean val-
ues, for the simple unidirectional multi-state model.
Model 1: Unidirectional Three-State Model
State Ever Wheeze Recurrent Wheeze
MLE 95% CI MLE 95% CI
No Wheeze 0.00059 0.00052; 0.00067 0a
Ever Wheeze -0.0012 -0.0015; -0.001 0.0012 0.001; 0.0015
Recurrent Wheeze 0 b -0 0; 0
a Transition intensities were defined as zero in the multi-state model for non-adjacent states.
b Unidirectional models did not allow for transitions into previous states, and thus transition intensities
were defined as zero.
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Table D4: Estimated 6-month transition probabilities for the simple unidirectional multi-state
model.
Model 1: Unidirectional Three-State Model
State No Wheeze Ever Wheeze Recurrent Wheeze
MLE 95% CI MLE 95% CI MLE 95% CI
No Wheeze 0.777 0.75; 0.802 0.171 0.149; 0.194 0.052 0.04; 0.068
Ever Wheeze 0 0; 0 0.585 0.492; 0.664 0.415 0.336; 0.508
Recurrent
Wheeze
0 0; 0 0 0; 0 1 1; 1
Table D5: Relative risks of wheeze and recurrent wheeze amongst children aged zero to three
years in the DCHS, using healthcare observed wheezing.
Variable First Wheeze First Recurrent WheezeHR 95% CI HR 95% CI
Exposure to other children
at home 1.04 0.95 - 1.15 1.16 1 - 1.35
Sex
Male 1.4 1.09 - 1.81 1.81 1.17 - 2.8
Female Reference
Prenatal Maternal Smoking
Yes 0.99 0.75 - 1.31 1.12 0.73 - 1.73
No Reference
Season of Birth
Winter (1 June – 31 August) 0.9 0.64 - 1.28 0.6 0.34 - 1.07
Spring (1 September – 30 November) 0.66 0.46 - 0.93 0.63 0.38 - 1.06
Summer (1 December – 28 February) 1.01 0.73 - 1.39 0.59 0.35 - 1.01
Autumn (1 March – 31 May) Reference
Hospitalization for Pneumonia
Hospitalized 1.82 1.34 - 2.48 2.39 1.48 - 3.87
Ambulatory Reference
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Table D6: Relative risks of wheeze and recurrent wheeze amongst children aged zero to three
years in the DCHS, using parentally reported wheezing.
Variable First Wheeze First Recurrent WheezeHR 95% CI HR 95% CI
Exposure to other children
at home 1.05 0.96 - 1.14 1.18 1.04 - 1.34
Sex
Male 1.09 0.89 - 1.35 1.23 0.9 - 1.66
Female Reference
Prenatal Maternal Smoking
Yes 1.1 0.87 - 1.4 1.25 0.9 - 1.76
No Reference
Season of Birth
Winter (1 June – 31 August) 0.78 0.59 - 1.02 0.76 0.51 - 1.15
Spring (1 September – 30 November) 0.66 0.5 - 0.88 0.67 0.44 - 1.01
Summer (1 December – 28 February) 0.75 0.57 - 1 0.72 0.48 - 1.08
Autumn (1 March – 31 May) Reference
Hospitalization for Pneumonia
Hospitalized 0.4 0.2 - 0.78 1.03 0.5 - 2.12
Ambulatory Reference
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